ZIVO Bioscience Reports Positive Efficacy Results from 42-Day Validation Study with Non-Antibiotic Immune-Modulating Product for the Prevention and Treatment of Coccidiosis in Broiler Chickens

Stock Information for Zivo Bioscience Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Zivo Bioscience Inc.

ZIVO Bioscience Reports Additional Findings from Positive 42-Day Coccidiosis Challenge Study
ZIVO Bioscience Announces Uplisting to OTCQB Market
ZIVO Bioscience Initiates 42-Day Validation Study with Immune-Modulating Product for the Prevention and Treatment of Coccidiosis in Broiler Chickens
ZIVO Bioscience Announces Reverse Stock Split
ZIVO Bioscience to Present at the Dawson James Small Cap Growth Conference
Dawson James Securities Announces October Date for 8th Annual Small Cap Growth Conference
Trial Results Confirm Efficacy of ZIVO Bioscience's Non-Antibiotic Product Candidate for the Prevention and Treatment of Coccidiosis in Broiler Chickens
ZIVO Announces Commitment by ZWorldwide to Purchase all Zivolife(TM) Algal Biomass Product Produced Over the Next 18 Months

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.